Ionis Pharmaceuticals to hold cardio-renal franchise webcast

Rhea-AI Summary

Ionis Pharmaceuticals will host a live webcast on September 2 at 10:00 a.m. ET to discuss its cardio-renal franchise. The 90-minute session will feature presentations from its executives, including Brett P. Monia and Sam Tsimikas. Key topics will include advances in RNA-targeted drug discovery and specific medicines aimed at treating triglyceride-driven diseases, thrombosis, and treatment-resistant hypertension. The webcast can be accessed at www.ionispharma.com.

Positive

• Hosting a webcast to discuss advancements in cardio-renal franchise, signaling transparency.
• In-depth presentations by key executives could enhance investor confidence.

Negative

• None.

CARLSBAD, Calif., Aug. 26, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, September 2^nd at 10:00 a.m. Eastern Time to review its cardio-renal franchise. The approximately 90-minute webcast will include presentations from Brett P. Monia, Ph.D., chief executive officer; Sam Tsimikas, M.D., senior vice president, global cardiovascular development; Sanjay Bhanot, M.D., Ph.D., chief medical officer; and Richard Geary, Ph.D., executive vice president, development. The agenda for the webcast will be as follows:

Welcome and Introductions	Wade Walke
Ionis – The Leader in RNA-targeted Drug Discovery and Development	Brett Monia
Ionis – Leading the Way in Targeting Cardiovascular and Renal Diseases	Sam Tsimikas
Medicines Targeting Triglyceride-driven Diseases ο    Akcea-APOCIII-LRx ο   Vupanorsen (AKCEA-ANGPTL3-LRx)	Sam Tsimikas
Thrombosis: IONIS-FXI-LRx	Sanjay Bhanot
Apolipoprotein(a): AKCEA-APO(a)-LRx	Sam Tsimikas
Transthyretin Amyloid Cardiomyopathy: AKCEA-TTR-LRx	Richard Geary
Treatment Resistant Hypertension: IONIS-AGT-LRx	Richard Geary
Conclusions	Brett Monia
Q&A	All

Interested parties may access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of disease, including neurological, cardio-renal, metabolic, infectious, and pulmonary diseases.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-cardio-renal-franchise-webcast-301118397.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

What is the date and time of Ionis Pharmaceuticals' webcast?

The webcast is scheduled for September 2 at 10:00 a.m. ET.

Who will present at the Ionis Pharmaceuticals webcast?

Presenters include Brett P. Monia, Sam Tsimikas, Sanjay Bhanot, and Richard Geary.

What topics will be covered in the Ionis Pharmaceuticals webcast?

The webcast will cover advancements in their cardio-renal franchise and specific treatment developments.

Where can I access the Ionis Pharmaceuticals webcast?

The webcast can be accessed at www.ionispharma.com.

How long will the Ionis Pharmaceuticals webcast last?

The webcast will last approximately 90 minutes.